

Publications Bernard Klein

Indice h = 98, Google scholar 4/3/2026

1. Rossi, J.-F., H.-C. Chiang, Z.-Y. Lu, K. Levon, F. van Rhee, K. Kanhai, D. C. Fajgenbaum, B. Klein. Optimisation of anti-interleukin-6 therapy: Precision medicine through mathematical modelling. *Frontiers in immunology*. **2022**. 13:919489. doi:10.3389/fimmu.2022.919489.
2. Rossi, J.-F., H.-C. Chiang, B. Klein. Tocilizumab in Treatment for Patients With COVID-19. *JAMA internal medicine*. **2021**. 181(7):1018-1019. doi:10.1001/jamainternmed.2021.0395.
3. Villard, O., M. Armanet, G. Couderc, C. Bony, J. Moreaux, D. Noël, J. De Vos, B. Klein, J.-L. Veyrune, A. Wojtusciszyn. Characterization of immortalized human islet stromal cells reveals a MSC-like profile with pancreatic features. *Stem cell research & therapy*. **2020**. 11(1):158. doi:10.1186/s13287-020-01649-z.
4. Requirand, G., N. Robert, S. Boireau, L. Vincent, A. Seckinger, S. Bouhya, P. Ceballos, G. Cartron, D. Hose, B. Klein, J. Moreaux. BrdU incorporation in multiparameter flow cytometry: A new cell cycle assessment approach in multiple myeloma. *Cytometry. Part B, Clinical cytometry*. **2019**. 96(3):209-214. doi:10.1002/cyto.b.21730.
5. Gourzones, C., C. Bellanger, S. Lamure, O. K. Gadacha, E. G. De Paco, L. Vincent, G. Cartron, B. Klein, J. Moreaux. Antioxidant Defenses Confer Resistance to High Dose Melphalan in Multiple Myeloma Cells. *Cancers*. **2019**. 11(4). doi:10.3390/cancers11040439.
6. Vikova, V., M. Jourdan, N. Robert, G. Requirand, S. Boireau, A. Bruyer, L. Vincent, G. Cartron, B. Klein, O. Elemento, A. Kassambara, J. Moreaux. Comprehensive characterization of the mutational landscape in multiple myeloma cell lines reveals potential drivers and pathways associated with tumor progression and drug resistance. *Theranostics*. **2019**. 9(2):540-553. doi:10.7150/thno.28374.
7. Alaterre, E., S. Raimbault, J.-M. Garcia, T. Rème, G. Requirand, B. Klein, J. Moreaux. Automated and simplified identification of normal and abnormal plasma cells in Multiple Myeloma by flow cytometry. *Cytometry. Part B, Clinical cytometry*. **2018**. 94(3):484-492. doi:10.1002/cyto.b.21590.
8. Bruyer, A., K. Maes, L. Herviou, A. Kassambara, A. Seckinger, G. Cartron, T. Rème, N. Robert, G. Requirand, S. Boireau, C. Müller-Tidow, J.-L. Veyrune, L. Vincent, S. Bouhya, H. Goldschmidt, K. Vanderkerken, D. Hose, B. Klein, E. De Bruyne, J. Moreaux. DNMTi/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cells. *British journal of cancer*. **2018**. 118(8):1062-1073. doi:10.1038/s41416-018-0025-x.

9. Alaterre, E., S. Raimbault, H. Goldschmidt, S. Bouhya, G. Requirand, N. Robert, S. Boireau, A. Seckinger, D. Hose, B. Klein, J. Moreaux. CD24, CD27, CD36 and CD302 gene expression for outcome prediction in patients with multiple myeloma. *Oncotarget*. **2017**. 8(58):98931-98944. doi:10.18632/oncotarget.22131.
10. Viziteu, E., B. Klein, J. Basbous, Y.-L. Lin, C. Hirtz, C. Gourzones, L. Tiers, A. Bruyer, L. Vincent, C. Grandmougin, A. Seckinger, H. Goldschmidt, A. Constantinou, P. Pasero, D. Hose, J. Moreaux. RECQ1 helicase is involved in replication stress survival and drug resistance in multiple myeloma. *Leukemia*. **2017**. 31(10):2104-2113. doi:10.1038/leu.2017.54.
11. Schoenhals, M., M. Jourdan, A. Bruyer, A. Kassambara, B. Klein, J. Moreaux. Hypoxia favors the generation of human plasma cells. *Cell cycle (Georgetown, Tex.)*. **2017**. 16(11):1104-1117. doi:10.1080/15384101.2017.1317408.
12. Kassambara, A., M. Jourdan, A. Bruyer, N. Robert, V. Pantesco, O. Elemento, B. Klein, J. Moreaux. Global miRNA expression analysis identifies novel key regulators of plasma cell differentiation and malignant plasma cell. *Nucleic acids research*. **2017**. 45(10):5639-5652. doi:10.1093/nar/gkx327.
13. Jourdan, M., N. Robert, M. Cren, C. Thibaut, C. Duperray, A. Kassambara, M. Cogné, K. Tarte, B. Klein, J. Moreaux. Characterization of human FCRL4-positive B cells. *PloS one*. **2017**. 12(6):e0179793. doi:10.1371/journal.pone.0179793.
14. Schoenhals, M., M. Jourdan, A. Seckinger, V. Pantesco, D. Hose, A. Kassambara, J. Moreaux, B. Klein. Forced KLF4 expression increases the generation of mature plasma cells and uncovers a network linked with plasma cell stage. *Cell cycle (Georgetown, Tex.)*. **2016**. 15(14):1919-1928. doi:10.1080/15384101.2016.1191709.
15. Jourdan, M., M. Cren, P. Schafer, N. Robert, C. Duperray, L. Vincent, P. Ceballos, G. Cartron, J.-F. Rossi, J. Moreaux, R. Chopra, B. Klein. Differential effects of lenalidomide during plasma cell differentiation. *Oncotarget*. **2016**. 7(19):28096-28111. doi:10.18632/oncotarget.8581.
16. Viziteu, E., C. Grandmougin, H. Goldschmidt, A. Seckinger, D. Hose, B. Klein, J. Moreaux. Chetomin, targeting HIF-1 α /p300 complex, exhibits antitumour activity in multiple myeloma. *British journal of cancer*. **2016**. 114(5):519-523. doi:10.1038/bjc.2016.20.
17. Herviou, L., G. Cavalli, G. Cartron, B. Klein, J. Moreaux. EZH2 in normal hematopoiesis and hematological malignancies. *Oncotarget*. **2016**. 7(3):2284-2296. doi:10.18632/oncotarget.6198.
18. Viziteu, E., A. Kassambara, P. Pasero, B. Klein, J. Moreaux. RECQ helicases are deregulated in hematological malignancies in association with a prognostic value. *Biomarker research*. **2016**. 4:3. doi:10.1186/s40364-016-0057-4.
19. Seckinger, A., T. Meißner, J. Moreaux, V. Benes, J. Hillengass, M. Castoldi, J.

- Zimmermann, A. D. Ho, A. Jauch, H. Goldschmidt, B. Klein, D. Hose. miRNAs in multiple myeloma--a survival relevant complex regulator of gene expression. *Oncotarget*. **2015**. 6(36):39165-39183. doi:10.18632/oncotarget.5381.
20. Vincent, L., P. Ceballos, C. Plassot, J. C. Ménière, P. Quittet, R. Navarro, C. Cyteval, V. Szablewski, Z. Y. Lu, T. Kanouni, J. Moreaux, G. Cartron, B. Klein, N. Fegueux. Factors influencing extramedullary relapse after allogeneic transplantation for multiple myeloma. *Blood cancer journal*. **2015**. 5(8):e341. doi:10.1038/bcj.2015.48.
 21. Bret, C., B. Klein, G. Cartron, J.-F. Schved, A. Constantinou, P. Pasero, J. Moreaux. DNA repair in diffuse large B-cell lymphoma: a molecular portrait. *British journal of haematology*. **2015**. 169(2):296-299. doi:10.1111/bjh.13206.
 22. Hassen, W., A. Kassambara, T. Reme, S. Sahota, A. Seckinger, L. Vincent, G. Cartron, J. Moreaux, D. Hose, B. Klein. Drug metabolism and clearance system in tumor cells of patients with multiple myeloma. *Oncotarget*. **2015**. 6(8):6431-6447. doi:10.18632/oncotarget.3237.
 23. Rossi, J.-F., Z.-Y. Lu, M. Jourdan, B. Klein. Interleukin-6 as a therapeutic target. *Clinical cancer research : an official journal of the American Association for Cancer Research*. **2015**. 21(6):1248-1257. doi:10.1158/1078-0432.CCR-14-2291.
 24. Weinhold, N., T. Meissner, D. C. Johnson, A. Seckinger, J. Moreaux, A. Försti, B. Chen, J. Nickel, D. Chubb, A. C. Rawstron, C. Doughty, N. B. Dahir, D. B. Begum, K. Young, B. A. Walker, P. Hoffmann, M. M. Nöthen, F. E. Davies, B. Klein, H. Goldschmidt, G. J. Morgan, R. S. Houlston, D. Hose, K. Hemminki. The 7p15.3 (rs4487645) association for multiple myeloma shows strong allele-specific regulation of the MYC-interacting gene CDCA7L in malignant plasma cells. *Haematologica*. **2015**. 100(3):e110-113. doi:10.3324/haematol.2014.118786.
 25. Waizenegger, J. S., I. Ben-Batalla, N. Weinhold, T. Meissner, M. Wroblewski, M. Janning, K. Riecken, M. Binder, D. Atanackovic, H. Taipaleenmaeki, D. Schewe, S. Sawall, V. Gensch, M. Cubas-Cordova, A. Seckinger, W. Fiedler, E. Hesse, N. Kröger, B. Fehse, D. Hose, B. Klein, M. S. Raab, K. Pantel, C. Bokemeyer, S. Loges. Role of Growth arrest-specific gene 6-Mer axis in multiple myeloma. *Leukemia*. **2015**. 29(3):696-704. doi:10.1038/leu.2014.236.
 26. Maes, K., E. De Smedt, A. Kassambara, D. Hose, A. Seckinger, E. Van Valckenborgh, E. Menu, B. Klein, K. Vanderkerken, J. Moreaux, E. De Bruyne. In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma. *Oncotarget*. **2015**. 6(5):3319-3334. doi:10.18632/oncotarget.3207.
 27. Bolomsky, A., D. Hose, M. Schreder, A. Seckinger, S. Lipp, B. Klein, D. Heintzel, H. Ludwig, N. Zojer. Insulin like growth factor binding protein 7 (IGFBP7) expression is linked to poor prognosis but may protect from bone disease in multiple myeloma. *Journal of hematology & oncology*. **2015**. 8:10. doi:10.1186/s13045-014-0105-1.

28. Kassambara, A., T. Rème, M. Jourdan, T. Fest, D. Hose, K. Tarte, B. Klein. GenomicScape: an easy-to-use web tool for gene expression data analysis. Application to investigate the molecular events in the differentiation of B cells into plasma cells. *PLoS computational biology*. **2015**. 11(1):e1004077. doi:10.1371/journal.pcbi.1004077.
29. Wagner, V., D. Hose, A. Seckinger, L. Weiz, T. Meißner, T. Rème, I. Breitkreutz, K. Podar, A. D. Ho, H. Goldschmidt, A. Krämer, B. Klein, M. S. Raab. Preclinical efficacy of sepantronium bromide (YM155) in multiple myeloma is conferred by down regulation of Mcl-1. *Oncotarget*. **2014**. 5(21):10237-10250. doi:10.18632/oncotarget.2529.
30. Jourdan, M., M. Cren, N. Robert, K. Bolloré, T. Fest, C. Duperray, F. Guilloton, D. Hose, K. Tarte, B. Klein. IL-6 supports the generation of human long-lived plasma cells in combination with either APRIL or stromal cell-soluble factors. *Leukemia*. **2014**. 28(8):1647-1656. doi:10.1038/leu.2014.61.
31. Kassambara, A., C. Gourzones-Dmitriev, S. Sahota, T. Rème, J. Moreaux, H. Goldschmidt, A. Constantinou, P. Pasero, D. Hose, B. Klein. A DNA repair pathway score predicts survival in human multiple myeloma: the potential for therapeutic strategy. *Oncotarget*. **2014**. 5(9):2487-2498. doi:10.18632/oncotarget.1740.
32. Moreaux, J., A. Bruyer, J.-L. Veyrune, H. Goldschmidt, D. Hose, B. Klein. DNA methylation score is predictive of myeloma cell sensitivity to 5-azacitidine. *British journal of haematology*. **2014**. 164(4):613-616. doi:10.1111/bjh.12660.
33. Bou Samra, E., B. Klein, T. Commes, J. Moreaux. Identification of a 20-gene expression-based risk score as a predictor of clinical outcome in chronic lymphocytic leukemia patients. *BioMed research international*. **2014**. 2014:423174. doi:10.1155/2014/423174.
34. Auger, S., M. Orsini, P. Cébaillos, N. Fegueux, T. Kanouni, B. Caumes, B. Klein, M. Villalba, J.-F. Rossi. Controlled Epstein-Barr virus reactivation after allogeneic transplantation is associated with improved survival. *European journal of haematology*. **2014**. 92(5):421-428. doi:10.1111/ejh.12260.
35. Gourzones-Dmitriev, C., A. Kassambara, S. Sahota, T. Rème, J. Moreaux, P. Bourquard, D. Hose, P. Pasero, A. Constantinou, B. Klein. DNA repair pathways in human multiple myeloma: role in oncogenesis and potential targets for treatment. *Cell cycle (Georgetown, Tex.)*. **2013**. 12(17):2760-2773. doi:10.4161/cc.25951.
36. Schoenhals, M., A. Kassambara, J.-L. Veyrune, J. Moreaux, H. Goldschmidt, D. Hose, B. Klein. Krüppel-like factor 4 blocks tumor cell proliferation and promotes drug resistance in multiple myeloma. *Haematologica*. **2013**. 98(9):1442-1449. doi:10.3324/haematol.2012.066944.
37. Moreaux, J., T. Rème, W. Leonard, J.-L. Veyrune, G. Requirand, H. Goldschmidt, D. Hose, B. Klein. Gene expression-based prediction of myeloma cell sensitivity to histone deacetylase inhibitors. *British journal of cancer*. **2013**. 109(3):676-685. doi:10.1038/bjc.2013.392.

38. Rème, T., D. Hose, C. Theillet, B. Klein. Modeling risk stratification in human cancer. *Bioinformatics (Oxford, England)*. **2013**. 29(9):1149-1157. doi:10.1093/bioinformatics/btt124.
39. Bai, Q., R. Desprat, B. Klein, J.-M. Lemaître, J. De Vos. Embryonic stem cells or induced pluripotent stem cells? A DNA integrity perspective. *Current gene therapy*. **2013**. 13(2):93-98. doi:10.2174/1566523211313020003.
40. Braza, M. S., B. Klein. Anti-tumour immunotherapy with V γ 9V δ 2 T lymphocytes: from the bench to the bedside. *British journal of haematology*. **2013**. 160(2):123-132. doi:10.1111/bjh.12090.
41. Moehler, T. M., A. Seckinger, D. Hose, M. Andrulis, J. Moreaux, T. Hielscher, M. Willhauck-Fleckenstein, A. Merling, U. Bertsch, A. Jauch, H. Goldschmidt, B. Klein, R. Schwartz-Albiez. The glycome of normal and malignant plasma cells. *PloS one*. **2013**. 8(12):e83719. doi:10.1371/journal.pone.0083719.
42. Kassambara, A., M. Schoenhals, J. Moreaux, J.-L. Veyrone, T. Rème, H. Goldschmidt, D. Hose, B. Klein. Inhibition of DEPDC1A, a bad prognostic marker in multiple myeloma, delays growth and induces mature plasma cell markers in malignant plasma cells. *PloS one*. **2013**. 8(4):e62752. doi:10.1371/journal.pone.0062752.
43. Moreaux, J., A. Kassambara, D. Hose, B. Klein. STEAP1 is overexpressed in cancers: a promising therapeutic target. *Biochemical and biophysical research communications*. **2012**. 429(3-4):148-155. doi:10.1016/j.bbrc.2012.10.123.
44. Moreaux, J., T. Rème, W. Leonard, J.-L. Veyrone, G. Requirand, H. Goldschmidt, D. Hose, B. Klein. Development of gene expression-based score to predict sensitivity of multiple myeloma cells to DNA methylation inhibitors. *Molecular cancer therapeutics*. **2012**. 11(12):2685-2692. doi:10.1158/1535-7163.MCT-12-0721.
45. Bret, C., B. Klein, J. Moreaux. Gene expression-based risk score in diffuse large B-cell lymphoma. *Oncotarget*. **2012**. 3(12):1700-1710. doi:10.18632/oncotarget.807.
46. Caraux, A., L. Vincent, S. Bouhya, P. Quittet, J. Moreaux, G. Requirand, J.-L. Veyrone, G. Olivier, G. Cartron, J.-F. Rossi, B. Klein. Residual malignant and normal plasma cells shortly after high dose melphalan and stem cell transplantation. Highlight of a putative therapeutic window in Multiple Myeloma? *Oncotarget*. **2012**. 3(11):1335-1347. doi:10.18632/oncotarget.650.
47. Bou Samra, E., B. Klein, T. Commes, J. Moreaux. Development of gene expression-based risk score in cytogenetically normal acute myeloid leukemia patients. *Oncotarget*. **2012**. 3(8):824-832. doi:10.18632/oncotarget.571.
48. Schoenhals, M., C. Frecha, A. Bruyer, A. Caraux, J. L. Veyrone, M. Jourdan, J. Moreaux, F.-L. Cosset, E. Verhoeyen, B. Klein. Efficient transduction of healthy and malignant plasma cells by lentiviral vectors pseudotyped with measles virus glycoproteins. *Leukemia*. **2012**. 26(7):1663-1670. doi:10.1038/leu.2012.36.

49. Chiron, D., S. Maïga, G. Descamps, P. Moreau, S. Le Gouill, S. Marionneau, T. Ouiller, J. Moreaux, B. Klein, R. Bataille, M. Amiot, C. Pellat-Deceunynck. Critical role of the NOTCH ligand JAG2 in self-renewal of myeloma cells. *Blood cells, molecules & diseases*. **2012**. 48(4):247-253. doi:10.1016/j.bcmd.2012.01.006.
50. Kassambara, A., D. Hose, J. Moreaux, B. A. Walker, A. Protopopov, T. Reme, F. Pellestor, V. Pantesco, A. Jauch, G. Morgan, H. Goldschmidt, B. Klein. Genes with a spike expression are clustered in chromosome (sub)bands and spike (sub)bands have a powerful prognostic value in patients with multiple myeloma. *Haematologica*. **2012**. 97(4):622-630. doi:10.3324/haematol.2011.046821.
51. Kassambara, A., D. Hose, J. Moreaux, T. Rème, J. Torrent, J. F. Rossi, H. Goldschmidt, B. Klein. Identification of pluripotent and adult stem cell genes unrelated to cell cycle and associated with poor prognosis in multiple myeloma. *PloS one*. **2012**. 7(7):e42161. doi:10.1371/journal.pone.0042161.
52. Jourdan, M., A. Caraux, G. Caron, N. Robert, G. Fiol, T. Rème, K. Bolloré, J.-P. Vendrell, S. Le Gallou, F. Mourcin, J. De Vos, A. Kassambara, C. Duperray, D. Hose, T. Fest, K. Tarte, B. Klein. Characterization of a transitional preplasmablast population in the process of human B cell to plasma cell differentiation. *Journal of immunology (Baltimore, Md. : 1950)*. **2011**. 187(8):3931-3941. doi:10.4049/jimmunol.1101230.
53. Bret, C., J. Moreaux, J.-F. Schved, D. Hose, B. Klein. SULFs in human neoplasia: implication as progression and prognosis factors. *Journal of translational medicine*. **2011**. 9:72. doi:10.1186/1479-5876-9-72.
54. Bret, C., D. Hose, T. Reme, A. Kassambara, A. Seckinger, T. Meissner, J.-F. Schved, T. Kanouni, H. Goldschmidt, B. Klein. Gene expression profile of ADAMs and ADAMTSs metalloproteinases in normal and malignant plasma cells and in the bone marrow environment. *Experimental hematology*. **2011**. 39(5):546-557.e8. doi:10.1016/j.exphem.2011.02.002.
55. Moreaux, J., B. Klein, R. Bataille, G. Descamps, S. Maïga, D. Hose, H. Goldschmidt, A. Jauch, T. Rème, M. Jourdan, M. Amiot, C. Pellat-Deceunynck. A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines. *Haematologica*. **2011**. 96(4):574-582. doi:10.3324/haematol.2010.033456.
56. Braza, M. S., B. Klein, G. Fiol, J.-F. Rossi. $\gamma\delta$ T-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody. *Haematologica*. **2011**. 96(3):400-407. doi:10.3324/haematol.2010.029520.
57. Caraux, A., M. Perez-Andres, M. Larroque, G. Requirand, Z.-Y. Lu, T. Kanouni, J. F. Rossi, A. Orfao, B. Klein. Mobilization of plasma cells in healthy individuals treated with granulocyte colony-stimulating factor for haematopoietic stem cell collection. *Immunology*. **2011**. 132(2):266-272. doi:10.1111/j.1365-2567.2010.03361.x.

58. Moreaux, J., D. Hose, A. Kassambara, T. Reme, P. Moine, G. Requirand, H. Goldschmidt, B. Klein. Osteoclast-gene expression profiling reveals osteoclast-derived CCR2 chemokines promoting myeloma cell migration. *Blood*. **2011**. 117(4):1280-1290. doi:10.1182/blood-2010-04-279760.
59. Moreaux, J., D. Hose, A. Bonnefond, T. Reme, N. Robert, H. Goldschmidt, B. Klein. MYEOV is a prognostic factor in multiple myeloma. *Experimental hematology*. **2010**. 38(12):1189-1198.e3. doi:10.1016/j.exphem.2010.09.002.
60. Sprynski, A. C., D. Hose, A. Kassambara, L. Vincent, M. Jourdan, J. F. Rossi, H. Goldschmidt, B. Klein. Insulin is a potent myeloma cell growth factor through insulin/IGF-1 hybrid receptor activation. *Leukemia*. **2010**. 24(11):1940-1950. doi:10.1038/leu.2010.192.
61. Caraux, A., B. Klein, B. Paiva, C. Bret, A. Schmitz, G. M. Fuhler, N. A. Bos, H. E. Johnsen, A. Orfao, M. Perez-Andres. Circulating human B and plasma cells. Age-associated changes in counts and detailed characterization of circulating normal CD138- and CD138+ plasma cells. *Haematologica*. **2010**. 95(6):1016-1020. doi:10.3324/haematol.2009.018689.
62. Mahtouk, K., J. Moreaux, D. Hose, T. Rème, T. Meissner, M. Jourdan, J. F. Rossi, S. T. Pals, H. Goldschmidt, B. Klein. Growth factors in multiple myeloma: a comprehensive analysis of their expression in tumor cells and bone marrow environment using Affymetrix microarrays. *BMC cancer*. **2010**. 10:198. doi:10.1186/1471-2407-10-198.
63. Klein, B. Positioning NK-kappaB in multiple myeloma. *Blood*. **2010**. 115(17):3422-3424. doi:10.1182/blood-2010-01-264796.
64. Tondeur, S., C. Pangault, T. Le Carrou, Y. Lannay, R. Benmahdi, A. Cubizolle, S. Assou, V. Pantesco, B. Klein, S. Hamamah, J.-F. Schved, T. Fest, J. De Vos. Expression map of the human exome in CD34+ cells and blood cells: increased alternative splicing in cell motility and immune response genes. *PloS one*. **2010**. 5(2):e8990. doi:10.1371/journal.pone.0008990.
65. Condomines, M., J.-L. Veyrune, M. Larroque, P. Quittet, P. Latry, C. Lugagne, C. Hertogh, T. Kanouni, J.-F. Rossi, B. Klein. Increased plasma-immune cytokines throughout the high-dose melphalan-induced lymphodepletion in patients with multiple myeloma: a window for adoptive immunotherapy. *Journal of immunology (Baltimore, Md. : 1950)*. **2010**. 184(2):1079-1084. doi:10.4049/jimmunol.0804159.
66. Jourdan, M., A. Caraux, J. De Vos, G. Fiol, M. Larroque, C. Cognot, C. Bret, C. Duperray, D. Hose, B. Klein. An in vitro model of differentiation of memory B cells into plasmablasts and plasma cells including detailed phenotypic and molecular characterization. *Blood*. **2009**. 114(25):5173-5181. doi:10.1182/blood-2009-07-235960.
67. Rossi, J.-F., J. Moreaux, D. Hose, G. Requirand, M. Rose, V. Rouillé, I. Nestorov, G. Mordenti, H. Goldschmidt, A. Ythier, B. Klein. Atacicept in relapsed/refractory multiple myeloma or active Waldenström's macroglobulinemia: a phase I study. *British journal of*

- cancer*. **2009**. 101(7):1051-1058. doi:10.1038/sj.bjc.6605241.
68. Moreaux, J., A.-C. Sprynski, S. R. Dillon, K. Mahtouk, M. Jourdan, A. Ythier, P. Moine, N. Robert, E. Jourdan, J. F. Rossi, B. Klein. APRIL and TACI interact with syndecan-1 on the surface of multiple myeloma cells to form an essential survival loop. *European journal of haematology*. **2009**. 83(2):119-129. doi:10.1111/j.1600-0609.2009.01262.x.
 69. Condomines, M., D. Hose, T. Rème, G. Requirand, M. Hundemer, M. Schoenhals, H. Goldschmidt, B. Klein. Gene expression profiling and real-time PCR analyses identify novel potential cancer-testis antigens in multiple myeloma. *Journal of immunology (Baltimore, Md. : 1950)*. **2009**. 183(2):832-840. doi:10.4049/jimmunol.0803298.
 70. Schoenhals, M., A. Kassambara, J. De Vos, D. Hose, J. Moreaux, B. Klein. Embryonic stem cell markers expression in cancers. *Biochemical and biophysical research communications*. **2009**. 383(2):157-162. doi:10.1016/j.bbrc.2009.02.156.
 71. Sprynski, A. C., D. Hose, L. Caillot, T. Réme, J. D. J. Shaughnessy, B. Barlogie, A. Seckinger, J. Moreaux, M. Hundemer, M. Jourdan, T. Meissner, A. Jauch, K. Mahtouk, A. Kassambara, U. Bertsch, J. F. Rossi, H. Goldschmidt, B. Klein. The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor. *Blood*. **2009**. 113(19):4614-4626. doi:10.1182/blood-2008-07-170464.
 72. Bret, C., D. Hose, T. Reme, A.-C. Sprynski, K. Mahtouk, J.-F. Schved, P. Quittet, J.-F. Rossi, H. Goldschmidt, B. Klein. Expression of genes encoding for proteins involved in heparan sulphate and chondroitin sulphate chain synthesis and modification in normal and malignant plasma cells. *British journal of haematology*. **2009**. 145(3):350-368. doi:10.1111/j.1365-2141.2009.07633.x.
 73. Jourdan, M., T. Reme, H. Goldschmidt, G. Fiol, V. Pantesco, J. De Vos, J.-F. Rossi, D. Hose, B. Klein. Gene expression of anti- and pro-apoptotic proteins in malignant and normal plasma cells. *British journal of haematology*. **2009**. 145(1):45-58. doi:10.1111/j.1365-2141.2008.07562.x.
 74. Moreaux, J., J.-L. Veyrune, J. De Vos, B. Klein. APRIL is overexpressed in cancer: link with tumor progression. *BMC cancer*. **2009**. 9:83. doi:10.1186/1471-2407-9-83.
 75. Kassambara, A., B. Klein, J. Moreaux. MMSET is overexpressed in cancers: link with tumor aggressiveness. *Biochemical and biophysical research communications*. **2009**. 379(4):840-845. doi:10.1016/j.bbrc.2008.12.093.
 76. Assou, S., D. Cerecedo, S. Tondeur, V. Pantesco, O. Hovatta, B. Klein, S. Hamamah, J. De Vos. A gene expression signature shared by human mature oocytes and embryonic stem cells. *BMC genomics*. **2009**. 10:10. doi:10.1186/1471-2164-10-10.
 77. Gasca, S., L. Reyftmann, F. Pellestor, T. Rème, S. Assou, T. Anahory, H. Dechaud, B. Klein, J. De Vos, S. Hamamah. Total fertilization failure and molecular abnormalities in metaphase II oocytes. *Reproductive biomedicine online*. **2008**. 17(6):772-781. doi:10.1016/s1472-6483(10)60404-x.

78. Haouzi, D., J. De Vos, V. Loup, S. Assou, S. Gasca, L. Reyftmann, B. Klein, S. Hamamah. [Oocyte and embryo quality: do the apoptotic markers have a place in the preimplantation genetic diagnostic?]. *Gynecologie, obstetrique & fertilité*. **2008**. 36(7-8):730-742. doi:10.1016/j.gyobfe.2008.02.028.
79. Cartron, G., L. Zhao-Yang, M. Baudard, T. Kanouni, V. Rouillé, P. Quittet, B. Klein, J.-F. Rossi. Granulocyte-macrophage colony-stimulating factor potentiates rituximab in patients with relapsed follicular lymphoma: results of a phase II study. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. **2008**. 26(16):2725-2731. doi:10.1200/JCO.2007.13.7729.
80. Moreaux, J., J. L. Veyrone, T. Rème, J. De Vos, B. Klein. CD200: a putative therapeutic target in cancer. *Biochemical and biophysical research communications*. **2008**. 366(1):117-122. doi:10.1016/j.bbrc.2007.11.103.
81. Rème, T., D. Hose, J. De Vos, A. Vassal, P.-O. Poulain, V. Pantesco, H. Goldschmidt, B. Klein. A new method for class prediction based on signed-rank algorithms applied to Affymetrix microarray experiments. *BMC bioinformatics*. **2008**. 9:16. doi:10.1186/1471-2105-9-16.
82. Mahtouk, K., D. Hose, J. De Vos, J. Moreaux, M. Jourdan, J. F. Rossi, T. Rème, H. Goldschmidt, B. Klein. Input of DNA microarrays to identify novel mechanisms in multiple myeloma biology and therapeutic applications. *Clinical cancer research : an official journal of the American Association for Cancer Research*. **2007**. 13(24):7289-7295. doi:10.1158/1078-0432.CCR-07-1758.
83. Burjanadzé, M., M. Condomines, T. Rème, P. Quittet, P. Latry, C. Lugagne, F. Romagne, Y. Morel, J. F. Rossi, B. Klein, Z. Y. Lu. In vitro expansion of gamma delta T cells with anti-myeloma cell activity by Phosphostim and IL-2 in patients with multiple myeloma. *British journal of haematology*. **2007**. 139(2):206-216. doi:10.1111/j.1365-2141.2007.06754.x.
84. Jourdan, M., J. Moreaux, J. D. Vos, D. Hose, K. Mahtouk, M. Abouladze, N. Robert, M. Baudard, T. Rème, A. Romanelli, H. Goldschmidt, J.-F. Rossi, M. Dreano, B. Klein. Targeting NF-kappaB pathway with an IKK2 inhibitor induces inhibition of multiple myeloma cell growth. *British journal of haematology*. **2007**. 138(2):160-168. doi:10.1111/j.1365-2141.2007.06629.x.
85. Mahtouk, K., D. Hose, P. Raynaud, M. Hundemer, M. Jourdan, E. Jourdan, V. Pantesco, M. Baudard, J. De Vos, M. Larroque, T. Moehler, J.-F. Rossi, T. Rème, H. Goldschmidt, B. Klein. Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma. *Blood*. **2007**. 109(11):4914-4923. doi:10.1182/blood-2006-08-043232.
86. Moreaux, J., D. Hose, M. Jourdan, T. Rème, M. Hundemer, M. Moos, N. Robert, P. Moine, J. De Vos, H. Goldschmidt, B. Klein. TACI expression is associated with a mature bone marrow plasma cell signature and C-MAF overexpression in human myeloma cell lines. *Haematologica*. **2007**. 92(6):803-811. doi:10.3324/haematol.10574.

87. Assou, S., T. Le Carrou, S. Tondeur, S. Ström, A. Gabelle, S. Marty, L. Nadal, V. Pantesco, T. Réme, J.-P. Hugnot, S. Gasca, O. Hovatta, S. Hamamah, B. Klein, J. De Vos. A meta-analysis of human embryonic stem cells transcriptome integrated into a web-based expression atlas. *Stem cells (Dayton, Ohio)*. **2007**. 25(4):961-973. doi:10.1634/stemcells.2006-0352.
88. Condomines, M., D. Hose, P. Raynaud, M. Hundemer, J. De Vos, M. Baudard, T. Moehler, V. Pantesco, M. Moos, J.-F. Schved, J.-F. Rossi, T. Rème, H. Goldschmidt, B. Klein. Cancer/testis genes in multiple myeloma: expression patterns and prognosis value determined by microarray analysis. *Journal of immunology (Baltimore, Md. : 1950)*. **2007**. 178(5):3307-3315. doi:10.4049/jimmunol.178.5.3307.
89. Lu, Z.-Y., M. Condomines, K. Tarte, L. Nadal, M. C. Delteil, J. F. Rossi, C. Ferrand, B. Klein. B7-1 and 4-1BB ligand expression on a myeloma cell line makes it possible to expand autologous tumor-specific cytotoxic T cells in vitro. *Experimental hematology*. **2007**. 35(3):443-453. doi:10.1016/j.exphem.2006.11.002.
90. Baudard, M., F. Comte, A. M. Conge, D. Mariano-Goulart, B. Klein, J. F. Rossi. Importance of [18F]fluorodeoxyglucose-positron emission tomography scanning for the monitoring of responses to immunotherapy in follicular lymphoma. *Leukemia & lymphoma*. **2007**. 48(2):381-388. doi:10.1080/10428190601094354.
91. Moreaux, J., D. Hose, T. Reme, E. Jourdan, M. Hundemer, E. Legouffe, P. Moine, P. Bourin, M. Moos, J. Corre, T. Möhler, J. De Vos, J. F. Rossi, H. Goldschmidt, B. Klein. CD200 is a new prognostic factor in multiple myeloma. *Blood*. **2006**. 108(13):4194-4197. doi:10.1182/blood-2006-06-029355.
92. Mahtouk, K., F. W. Cremer, T. Rème, M. Jourdan, M. Baudard, J. Moreaux, G. Requirand, G. Fiol, J. De Vos, M. Moos, P. Quittet, H. Goldschmidt, J.-F. Rossi, D. Hose, B. Klein. Heparan sulphate proteoglycans are essential for the myeloma cell growth activity of EGF-family ligands in multiple myeloma. *Oncogene*. **2006**. 25(54):7180-7191. doi:10.1038/sj.onc.1209699.
93. Quittet, P., P. Ceballos, E. Lopez, Z. Y. Lu, P. Latry, C. Becht, E. Legouffe, N. Fegueux, C. Exbrayat, D. Pouessel, V. Rouillé, J. P. Daures, B. Klein, J. F. Rossi. Low doses of GM-CSF (molgramostim) and G-CSF (filgrastim) after cyclophosphamide (4 g/m²) enhance the peripheral blood progenitor cell harvest: results of two randomized studies including 120 patients. *Bone marrow transplantation*. **2006**. 38(4):275-284. doi:10.1038/sj.bmt.1705441.
94. Assou, S., T. Anahory, V. Pantesco, T. Le Carrou, F. Pellestor, B. Klein, L. Reyftmann, H. Dechaud, J. De Vos, S. Hamamah. The human cumulus--oocyte complex gene-expression profile. *Human reproduction (Oxford, England)*. **2006**. 21(7):1705-1719. doi:10.1093/humrep/del065.
95. Condomines, M., P. Quittet, Z.-Y. Lu, L. Nadal, P. Latry, E. Lopez, M. Baudard, G. Requirand, C. Duperray, J.-F. Schved, J.-F. Rossi, K. Tarte, B. Klein. Functional regulatory T cells are collected in stem cell autografts by mobilization with high-dose

- cyclophosphamide and granulocyte colony-stimulating factor. *Journal of immunology (Baltimore, Md. : 1950)*. **2006**. 176(11):6631-6639. doi:10.4049/jimmunol.176.11.6631.
96. De Vos, J., D. Hose, T. Rème, K. Tarte, J. Moreaux, K. Mahtouk, M. Jourdan, H. Goldschmidt, J.-F. Rossi, F. W. Cremer, B. Klein. Microarray-based understanding of normal and malignant plasma cells. *Immunological reviews*. **2006**. 210:86-104. doi:10.1111/j.0105-2896.2006.00362.x.
97. Rossi, J.-F., N. Fegueux, Z. Y. Lu, E. Legouffe, C. Exbrayat, M.-C. Bozonnat, R. Navarro, E. Lopez, P. Quittet, J.-P. Daures, V. Rouillé, T. Kanouni, J. Widjenes, B. Klein. Optimizing the use of anti-interleukin-6 monoclonal antibody with dexamethasone and 140 mg/m² of melphalan in multiple myeloma: results of a pilot study including biological aspects. *Bone marrow transplantation*. **2005**. 36(9):771-779. doi:10.1038/sj.bmt.1705138.
98. Moreaux, J., F. W. Cremer, T. Reme, M. Raab, K. Mahtouk, P. Kaukel, V. Pantesco, J. De Vos, E. Jourdan, A. Jauch, E. Legouffe, M. Moos, G. Fiol, H. Goldschmidt, J. F. Rossi, D. Hose, B. Klein. The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature. *Blood*. **2005**. 106(3):1021-1030. doi:10.1182/blood-2004-11-4512.
99. Mahtouk, K., D. Hose, T. Rème, J. De Vos, M. Jourdan, J. Moreaux, G. Fiol, M. Raab, E. Jourdan, V. Grau, M. Moos, H. Goldschmidt, M. Baudard, J. F. Rossi, F. W. Cremer, B. Klein. Expression of EGF-family receptors and amphiregulin in multiple myeloma. Amphiregulin is a growth factor for myeloma cells. *Oncogene*. **2005**. 24(21):3512-3524. doi:10.1038/sj.onc.1208536.
100. Jourdan, M., K. Mahtouk, J.-L. Veyrune, G. Couderc, G. Fiol, N. Redal, C. Duperray, J. De Vos, B. Klein. Delineation of the roles of paracrine and autocrine interleukin-6 (IL-6) in myeloma cell lines in survival versus cell cycle. A possible model for the cooperation of myeloma cell growth factors. *European cytokine network*. **2005**. 16(1):57-64. PMID:15809207.
101. Tarte, K., M. Jourdan, J. L. Veyrune, I. Berberich, G. Fiol, N. Redal, J. J. Shaughnessy, B. Klein. The Bcl-2 family member Bfl-1/A1 is strongly repressed in normal and malignant plasma cells but is a potent anti-apoptotic factor for myeloma cells. *British journal of haematology*. **2004**. 125(3):373-382. doi:10.1111/j.1365-2141.2004.04908.x.
102. Moreaux, J., E. Legouffe, E. Jourdan, P. Quittet, T. Rème, C. Lugagne, P. Moine, J.-F. Rossi, B. Klein, K. Tarte. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. *Blood*. **2004**. 103(8):3148-3157. doi:10.1182/blood-2003-06-1984.
103. Mahtouk, K., M. Jourdan, J. De Vos, C. Hertogh, G. Fiol, E. Jourdan, J.-F. Rossi, B. Klein. An inhibitor of the EGF receptor family blocks myeloma cell growth factor activity of HB-EGF and potentiates dexamethasone or anti-IL-6 antibody-induced apoptosis. *Blood*. **2004**. 103(5):1829-1837. doi:10.1182/blood-2003-05-1510.

104. De Vos, J., C. Bagnis, L. Bonnafoux, G. Requirand, M. Jourdan, M.-C. Imbert, E. Jourdan, J.-F. Rossi, P. Mannoni, B. Klein. Comparison of murine leukemia virus, human immunodeficiency virus, and adeno-associated virus vectors for gene transfer in multiple myeloma: lentiviral vectors demonstrate a striking capacity to transduce low-proliferating primary tumor cells. *Human gene therapy*. **2003**. 14(18):1727-1739. doi:10.1089/104303403322611746.
105. Klein, B., K. Tarte, M. Jourdan, K. Mathouk, J. Moreaux, E. Jourdan, E. Legouffe, J. De Vos, J. F. Rossi. Survival and proliferation factors of normal and malignant plasma cells. *International journal of hematology*. **2003**. 78(2):106-113. doi:10.1007/BF02983377.
106. Tarte, K., F. Zhan, J. De Vos, B. Klein, J. J. Shaughnessy. Gene expression profiling of plasma cells and plasmablasts: toward a better understanding of the late stages of B-cell differentiation. *Blood*. **2003**. 102(2):592-600. doi:10.1182/blood-2002-10-3161.
107. Jourdan, M., J.-L. Veyrune, J. De Vos, N. Redal, G. Couderc, B. Klein. A major role for Mcl-1 antiapoptotic protein in the IL-6-induced survival of human myeloma cells. *Oncogene*. **2003**. 22(19):2950-2959. doi:10.1038/sj.onc.1206423.
108. De Vos, J., T. Thykjaer, K. Tarte, M. Ensslen, P. Raynaud, G. Requirand, F. Pellet, V. Pantesco, T. Rème, M. Jourdan, J.-F. Rossi, T. Ørntoft, B. Klein. Comparison of gene expression profiling between malignant and normal plasma cells with oligonucleotide arrays. *Oncogene*. **2002**. 21(44):6848-6857. doi:10.1038/sj.onc.1205868.
109. Tarte, K., J. De Vos, T. Thykjaer, F. Zhan, G. Fiol, V. Costes, T. Rème, E. Legouffe, J.-F. Rossi, J. J. Shaughnessy, T. F. Ørntoft, B. Klein. Generation of polyclonal plasmablasts from peripheral blood B cells: a normal counterpart of malignant plasmablasts. *Blood*. **2002**. 100(4):1113-1122. PMID:12149187.
110. Wang, Y. D., J. De Vos, M. Jourdan, G. Couderc, Z.-Y. Lu, J.-F. Rossi, B. Klein. Cooperation between heparin-binding EGF-like growth factor and interleukin-6 in promoting the growth of human myeloma cells. *Oncogene*. **2002**. 21(16):2584-2592. doi:10.1038/sj.onc.1205355.
111. De Vos, J., G. Couderc, K. Tarte, M. Jourdan, G. Requirand, M. C. Delteil, J. F. Rossi, N. Mechti, B. Klein. Identifying intercellular signaling genes expressed in malignant plasma cells by using complementary DNA arrays. *Blood*. **2001**. 98(3):771-780. doi:10.1182/blood.v98.3.771.
112. Rème, T., E. Gueydon, C. Jacquet, B. Klein, J. Brochier. Growth and immortalization of human myeloma cells in immunodeficient severe combined immunodeficiency mice: a preclinical model. *British journal of haematology*. **2001**. 114(2):406-413. doi:10.1046/j.1365-2141.2001.02947.x.
113. Mohty, M., N. Fegueux, C. Exbrayat, Z. Y. Lu, E. Legouffe, P. Quittet, E. Lopez-Martinez, P. Latry, O. Avinens, C. Hertog, B. Klein, J. F. Eliaou, J. F. Rossi. Reduced intensity conditioning: enhanced graft-versus-tumor effect following dose-reduced conditioning and allogeneic transplantation for refractory lymphoid malignancies after high-dose therapy.

- Bone marrow transplantation*. **2001**. 28(4):335-339. doi:10.1038/sj.bmt.1703134.
114. Vincent, T., M. Jourdan, M. S. Sy, B. Klein, N. Mechti. Hyaluronic acid induces survival and proliferation of human myeloma cells through an interleukin-6-mediated pathway involving the phosphorylation of retinoblastoma protein. *The Journal of biological chemistry*. **2001**. 276(18):14728-14736. doi:10.1074/jbc.M003965200.
 115. Tarte, K., G. Fiol, J. F. Rossi, B. Klein. Extensive characterization of dendritic cells generated in serum-free conditions: regulation of soluble antigen uptake, apoptotic tumor cell phagocytosis, chemotaxis and T cell activation during maturation in vitro. *Leukemia*. **2000**. 14(12):2182-2192. doi:10.1038/sj.leu.2401925.
 116. Jourdan, M., J. De Vos, N. Mechti, B. Klein. Regulation of Bcl-2-family proteins in myeloma cells by three myeloma survival factors: interleukin-6, interferon-alpha and insulin-like growth factor 1. *Cell death and differentiation*. **2000**. 7(12):1244-1252. doi:10.1038/sj.cdd.4400758.
 117. Ferlin, M., N. Noraz, C. Hertogh, J. Brochier, N. Taylor, B. Klein. Insulin-like growth factor induces the survival and proliferation of myeloma cells through an interleukin-6-independent transduction pathway. *British journal of haematology*. **2000**. 111(2):626-634. doi:10.1046/j.1365-2141.2000.02364.x.
 118. De Vos, J., M. Jourdan, K. Tarte, C. Jasmin, B. Klein. JAK2 tyrosine kinase inhibitor tyrphostin AG490 downregulates the mitogen-activated protein kinase (MAPK) and signal transducer and activator of transcription (STAT) pathways and induces apoptosis in myeloma cells. *British journal of haematology*. **2000**. 109(4):823-828. doi:10.1046/j.1365-2141.2000.02127.x.
 119. Gu, Z. J., J. De Vos, C. Rebouissou, M. Jourdan, X. G. Zhang, J. F. Rossi, J. Wijdenes, B. Klein. Agonist anti-gp130 transducer monoclonal antibodies are human myeloma cell survival and growth factors. *Leukemia*. **2000**. 14(1):188-197. doi:10.1038/sj.leu.2401632.
 120. Zhou, Z. H., J. F. Wang, Y. D. Wang, Y. H. Qiu, J. Z. Pan, W. Xie, L. Y. Jiang, B. Klein, X. G. Zhang. An agonist anti-human CD40 monoclonal antibody that induces dendritic cell formation and maturation and inhibits proliferation of a myeloma cell line. *Hybridoma*. **1999**. 18(6):471-478. doi:10.1089/hyb.1999.18.471.
 121. Costes, V., V. Magen, E. Legouffe, L. Durand, P. Baldet, J. F. Rossi, B. Klein, J. Brochier. The Mi15 monoclonal antibody (anti-syndecan-1) is a reliable marker for quantifying plasma cells in paraffin-embedded bone marrow biopsy specimens. *Human pathology*. **1999**. 30(12):1405-1411. doi:10.1016/s0046-8177(99)90160-0.
 122. Gaillard, J., M. Pugnère, J. Tresca, J. Mani, B. Klein, J. Brochier. Interleukin-6 receptor signaling. II. Bio-availability of interleukin-6 in serum. *European cytokine network*. **1999**. 10(3):337-344. PMID:10477390.
 123. Tarte, K., X. G. Zhang, E. Legouffe, C. Hertog, M. Mehtali, J. F. Rossi, B. Klein. Induced expression of B7-1 on myeloma cells following retroviral gene transfer results in tumor-

- specific recognition by cytotoxic T cells. *Journal of immunology (Baltimore, Md. : 1950)*. **1999**. 163(1):514-524. PMID:10384156.
124. Klein, B., Z. Y. Lu, Z. J. Gu, V. Costes, M. Jourdan, J. F. Rossi. Interleukin-10 and Gp130 cytokines in human multiple myeloma. *Leukemia & lymphoma*. **1999**. 34(1-2):63-70. doi:10.3109/10428199909083381.
 125. Tarte, K., Y. Chang, B. Klein. Kaposi's sarcoma-associated herpesvirus and multiple myeloma: lack of criteria for causality. *Blood*. **1999**. 93(10):3159-63; discussion 3163-3164. PMID:10233868.
 126. Tarte, K., B. Klein. Dendritic cell-based vaccine: a promising approach for cancer immunotherapy. *Leukemia*. **1999**. 13(5):653-663. doi:10.1038/sj.leu.2401394.
 127. Jourdan, M., K. Tarte, E. Legouffe, J. Brochier, J. F. Rossi, B. Klein. Tumor necrosis factor is a survival and proliferation factor for human myeloma cells. *European cytokine network*. **1999**. 10(1):65-70. PMID:10210775.
 128. Gaillard, J. P., J. C. Mani, J. Liautard, B. Klein, J. Brochier. Interleukin-6 receptor signaling. I. gp80 and gp130 receptor interaction in the absence of interleukin-6. *European cytokine network*. **1999**. 10(1):43-48. PMID:10210772.
 129. Klein, B., X. Y. Li, Z. Y. Lu, M. Jourdan, K. Tarte, J. Brochier, E. Claret, J. Wijdenes, J. F. Rossi. Activation molecules on human myeloma cells. *Current topics in microbiology and immunology*. **1999**. 246:335-341. doi:10.1007/978-3-642-60162-0_41.
 130. Tupitsyn, N., Z. Kadagidze, J. P. Gaillard, E. Sholokhova, L. Andreeva, J. Liautard, C. Duperray, B. Klein, J. Brochier. Functional interaction of the gp80 and gp130 IL-6 receptors in human B cell malignancies. *Clinical and laboratory haematology*. **1998**. 20(6):345-352. doi:10.1046/j.1365-2257.1998.00162.x.
 131. Costes, V., M. Portier, Z. Y. Lu, J. F. Rossi, R. Bataille, B. Klein. Interleukin-1 in multiple myeloma: producer cells and their role in the control of IL-6 production. *British journal of haematology*. **1998**. 103(4):1152-1160. doi:10.1046/j.1365-2141.1998.01101.x.
 132. Autissier, P., J. De Vos, J. Liautard, N. Tupitsyn, C. Jacquet, N. Chavdia, B. Klein, J. Brochier, J. P. Gaillard. Dimerization and activation of the common transducing chain (gp130) of the cytokines of the IL-6 family by mAb. *International immunology*. **1998**. 10(12):1881-1889. doi:10.1093/intimm/10.12.1881.
 133. Olsen, S. J., K. Tarte, W. Sherman, E. E. Hale, M. T. Weisse, A. Orazi, B. Klein, Y. Chang. Evidence against KSHV infection in the pathogenesis of multiple myeloma. *Virus Research*. **1998**. 57(2):197-202. doi:10.1016/s0168-1702(98)00074-4.
 134. Legouffe, E., C. Rodriguez, M. C. Picot, B. Richard, B. Klein, J. F. Rossi, T. Commes. C-reactive protein serum level is a valuable and simple prognostic marker in non Hodgkin's lymphoma. *Leukemia & Lymphoma*. **1998**. 31(3-4):351-357. doi:10.3109/10428199809059228.

135. Ferlin-Bezombes, M., M. Jourdan, J. Liautard, J. Brochier, J. F. Rossi, B. Klein. IFN-alpha is a survival factor for human myeloma cells and reduces dexamethasone-induced apoptosis. *Journal of immunology (Baltimore, Md. : 1950)*. **1998**. 161(6):2692-2699. PMID:9743325.
136. Rao, P. H., J. C. Cigudosa, Y. Ning, M. J. Calasanz, S. Iida, S. Tagawa, J. Michaeli, B. Klein, R. Dalla-Favera, S. C. Jhanwar, T. Ried, R. S. Chaganti. Multicolor spectral karyotyping identifies new recurring breakpoints and translocations in multiple myeloma. *Blood*. **1998**. 92(5):1743-1748. PMID:9716604.
137. Rebouissou, C., J. Wijdenes, P. Autissier, K. Tarte, V. Costes, J. Liautard, J. F. Rossi, J. Brochier, B. Klein. A gp130 interleukin-6 transducer-dependent SCID model of human multiple myeloma. *Blood*. **1998**. 91(12):4727-4737. PMID:9616171.
138. Klein, B. Update of gp130 cytokines in multiple myeloma. *Current opinion in hematology*. **1998**. 5(3):186-191. doi:10.1097/00062752-199805000-00007.
139. Greipp, P. R., T. Leong, J. M. Bennett, J. P. Gaillard, B. Klein, J. A. Stewart, M. M. Oken, N. E. Kay, B. Van Ness, R. A. Kyle. Plasmablastic morphology--an independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) myeloma trial E9486 report by the ECOG Myeloma Laboratory Group. *Blood*. **1998**. 91(7):2501-2507. PMID:9516151.
140. Zhang, X. G., D. Olive, J. Devos, C. Rebouissou, M. Ghiotto-Ragueneau, M. Ferlin, B. Klein. Malignant plasma cell lines express a functional CD28 molecule. *Leukemia*. **1998**. 12(4):610-618. doi:10.1038/sj.leu.2400971.
141. Sun, R. X., J. Coste, C. Segara, T. Rousset, M. Fabbro, T. Rème, E. Legouffe, B. Klein, J. F. Rossi. MBR rearrangement and P-glycoprotein expression are not independent prognostic factors like p53 protein in malignant lymphoma. *Clinical and laboratory haematology*. **1998**. 20(2):87-94. doi:10.1046/j.1365-2257.1998.00090.x.
142. Tarte, K., S. J. Olsen, Z. Yang Lu, E. Legouffe, J. F. Rossi, Y. Chang, B. Klein. Clinical-grade functional dendritic cells from patients with multiple myeloma are not infected with Kaposi's sarcoma-associated herpesvirus. *Blood*. **1998**. 91(6):1852-1857. PMID:9490666.
143. Jourdan, M., M. Ferlin, E. Legouffe, M. Horvathova, J. Liautard, J. F. Rossi, J. Wijdenes, J. Brochier, B. Klein. The myeloma cell antigen syndecan-1 is lost by apoptotic myeloma cells. *British journal of haematology*. **1998**. 100(4):637-646. doi:10.1046/j.1365-2141.1998.00623.x.
144. Gaillard, J. P., J. Liautard, B. Klein, J. Brochier. Major role of the soluble interleukin-6/interleukin-6 receptor complex for the proliferation of interleukin-6-dependent human myeloma cell lines. *European journal of immunology*. **1997**. 27(12):3332-3340. doi:10.1002/eji.1830271232.
145. Tarte, K., Z. Y. Lu, G. Fiol, E. Legouffe, J. F. Rossi, B. Klein. Generation of virtually pure and potentially proliferating dendritic cells from non-CD34 apheresis cells from patients

- with multiple myeloma. *Blood*. **1997**. 90(9):3482-3495. PMID:9345032.
146. Iida, S., P. H. Rao, M. Butler, P. Corradini, M. Boccadoro, B. Klein, R. S. Chaganti, R. Dalla-Favera. Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma. *Nature Genetics*. **1997**. 17(2):226-230. doi:10.1038/ng1097-226.
 147. Klein, B. GP130 cytokines, interferon, survival and proliferation of human myeloma cells. *European cytokine network*. **1997**. 8(3):323. PMID:9346376.
 148. Diamant, M., K. Rieneck, N. Mechti, X. G. Zhang, M. Svenson, K. Bendtzen, B. Klein. Cloning and expression of an alternatively spliced mRNA encoding a soluble form of the human interleukin-6 signal transducer gp130. *FEBS letters*. **1997**. 412(2):379-384. doi:10.1016/s0014-5793(97)00750-3.
 149. Sun, R. X., Z. Y. Lu, J. Wijdenes, J. Brochier, C. Hertog, J. F. Rossi, B. Klein. Large scale and clinical grade purification of syndecan-1+ malignant plasma cells. *Journal of immunological methods*. **1997**. 205(1):73-79. doi:10.1016/s0022-1759(97)00056-2.
 150. Savino, R., A. Demartis, L. Ciapponi, E. Sporeno, C. Toniatti, F. Bernassola, G. Melino, B. Klein, G. Ciliberto. The receptor super-antagonist Sant7. *Oncology reports*. **1997**. 4(3):485-492. doi:10.3892/or.4.3.485.
 151. Liautard, J., R. X. Sun, N. Cotte, J. P. Gaillard, J. C. Mani, B. Klein, J. Brochier. Specific inhibition of IL-6 signalling with monoclonal antibodies against the gp130 receptor. *Cytokine*. **1997**. 9(4):233-241. doi:10.1006/cyto.1996.0159.
 152. Sun, R. X., C. Gennaro, S. Rocco, Z. J. Gu, B. Klein. Interleukin-6 receptor antagonists inhibit interleukin-11 biological activity. *European cytokine network*. **1997**. 8(1):51-56. PMID:9110148.
 153. Tissot, C., C. Rebouissou, B. Klein, N. Mechti. Both human alpha/beta and gamma interferons upregulate the expression of CD48 cell surface molecules. *Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research*. **1997**. 17(1):17-26. doi:10.1089/jir.1997.17.17.
 154. Savino, R., A. Demartis, L. Ciapponi, E. Sporeno, C. Toniatti, F. Bernassola, G. Melino, B. Klein, G. Ciliberto. The receptor super-antagonist Sant7. *Oncology Reports*. **1997**. 4(3):485-492. doi:10.3892/or.4.3.485.
 155. Gu, Z. J., V. Costes, Z. Y. Lu, X. G. Zhang, V. Pitard, J. F. Moreau, R. Bataille, J. Wijdenes, J. F. Rossi, B. Klein. Interleukin-10 is a growth factor for human myeloma cells by induction of an oncostatin M autocrine loop. *Blood*. **1996**. 88(10):3972-3986. PMID:8916964.
 156. Peest, D., J. Bladé, J. L. Harousseau, B. Klein, A. Osterborg, J. F. San Miguel. Cytokine therapy in multiple myeloma. *British Journal of Haematology*. **1996**. 94(3):425-432. doi:10.1046/j.1365-2141.1996.02298.x.

157. Gaillard, J. P., J. Liautard, J. C. Mani, J. M. Fernandez Suarez, B. Klein, J. Brochier. Identification of a novel antigenic structure of the human receptor for interleukin-6 involved in the interaction with the glycoprotein 130 chain. *Immunology*. **1996**. 89(1):135-141. doi:10.1046/j.1365-2567.1996.d01-709.x.
158. Wijdenes, J., W. C. Vooijs, C. Clément, J. Post, F. Morard, N. Vita, P. Laurent, R. X. Sun, B. Klein, J. M. Dore. A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1. *British Journal of Haematology*. **1996**. 94(2):318-323. doi:10.1046/j.1365-2141.1996.d01-1811.x.
159. Gu, Z. J., X. G. Zhang, M. M. Hallet, Z. Y. Lu, J. Wijdenes, J. F. Rossi, B. Klein. A ciliary neurotrophic factor-sensitive human myeloma cell line. *Experimental Hematology*. **1996**. 24(10):1195-1200. PMID:8765494.
160. Sporeno, E., R. Savino, L. Ciapponi, G. Paonessa, A. Cabibbo, A. Lahm, K. Pulkki, R. X. Sun, C. Toniatti, B. Klein, G. Ciliberto. Human interleukin-6 receptor super-antagonists with high potency and wide spectrum on multiple myeloma cells. *Blood*. **1996**. 87(11):4510-4519. PMID:8639818.
161. Harousseau, J., B. Klein. Utilisation de l'interféron alpha dans le myélome multiple. *La Revue de Médecine Interne*. **1996**. 17(6):488-495. doi:10.1016/0248-8663(96)86444-7.
162. Gu, Z. J., J. Wijdenes, X. G. Zhang, M. M. Hallet, C. Clement, B. Klein. Anti-gp130 transducer monoclonal antibodies specifically inhibiting ciliary neurotrophic factor, interleukin-6, interleukin-11, leukemia inhibitory factor or oncostatin M. *Journal of immunological methods*. **1996**. 190(1):21-27. doi:10.1016/0022-1759(95)00232-4.
163. Harousseau, J. L., B. Klein. [Use of interferon alpha in multiple myeloma]. *La Revue de medecine interne*. **1996**. 17(6):488-495. doi:10.1016/0248-8663(96)86444-7.
164. Lu, Z. Y., Z. J. Gu, X. G. Zhang, J. Wijdenes, P. Neddermann, J. F. Rossi, B. Klein. Interleukin-10 induces interleukin-11 responsiveness in human myeloma cell lines. *FEBS letters*. **1995**. 377(3):515-518. doi:10.1016/0014-5793(95)01322-9.
165. Wijdenes, J., P. C. Heinrich, G. Müller-Newen, C. Roche, Z. J. Gu, C. Clément, B. Klein. Interleukin-6 signal transducer gp130 has specific binding sites for different cytokines as determined by antagonistic and agonistic anti-gp130 monoclonal antibodies. *European Journal of Immunology*. **1995**. 25(12):3474-3481. doi:10.1002/eji.1830251240.
166. Lu, Z. Y., H. Brailly, J. Wijdenes, R. Bataille, J. F. Rossi, B. Klein. Measurement of whole body interleukin-6 (IL-6) production: prediction of the efficacy of anti-IL-6 treatments. *Blood*. **1995**. 86(8):3123-3131. PMID:7579407.
167. Lu, Z. Y., R. Bataille, P. Poubelle, M. J. Rapp, J. L. Harousseau, B. Klein. An interleukin 1 receptor antagonist blocks the IL-1-induced IL-6 paracrine production through a prostaglandin E2-related mechanism in multiple myeloma. *Stem cells (Dayton, Ohio)*. **1995**. 13 Suppl 2:28-34. PMID:8520508.

168. Bataille, R., B. Barlogie, Z. Y. Lu, J. F. Rossi, T. Lavabre-Bertrand, T. Beck, J. Wijdenes, J. Brochier, B. Klein. Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. *Blood*. **1995**. 86(2):685-691. PMID:7605999.
169. Lu, Z. Y., X. G. Zhang, C. Rodriguez, J. Wijdenes, Z. J. Gu, B. Morel-Fournier, J. L. Harousseau, R. Bataille, J. F. Rossi, B. Klein. Interleukin-10 is a proliferation factor but not a differentiation factor for human myeloma cells. *Blood*. **1995**. 85(9):2521-2527. PMID:7727780.
170. Klein, B., H. Brailly. Cytokine-binding proteins: stimulating antagonists. *Immunology today*. **1995**. 16(5):216-220. doi:10.1016/0167-5699(95)80161-8.
171. Montero-Julian, F. A., B. Klein, E. Gautherot, H. Brailly. Pharmacokinetic study of anti-interleukin-6 (IL-6) therapy with monoclonal antibodies: enhancement of IL-6 clearance by cocktails of anti-IL-6 antibodies. *Blood*. **1995**. 85(4):917-924. PMID:7849313.
172. Klein, B., X. G. Zhang, Z. Y. Lu, R. Bataille. Interleukin-6 in human multiple myeloma. *Blood*. **1995**. 85(4):863-872. PMID:7849308.
173. Klein, B. Cytokine, cytokine receptors, transduction signals, and oncogenes in human multiple myeloma. *Seminars in hematology*. **1995**. 32(1):4-19. PMID:7878477.
174. Brochier, J., E. Legouffe, J. Liautard, J. P. Gaillard, L. Q. Mao, R. Bataille, J. F. Rossi, B. Klein. Immunomodulating IL-6 activity by murine monoclonal antibodies. *International journal of immunopharmacology*. **1995**. 17(1):41-48. doi:10.1016/0192-0561(94)00076-z.
175. Legouffe, E., J. Liautard, J. P. Gaillard, J. F. Rossi, J. Wijdenes, R. Bataille, B. Klein, J. Brochier. Human anti-mouse antibody response to the injection of murine monoclonal antibodies against IL-6. *Clinical and experimental immunology*. **1994**. 98(2):323-329. doi:10.1111/j.1365-2249.1994.tb06145.x.
176. Lu, Z. Y., X. G. Zhang, Z. J. Gu, K. Yasukawa, M. Amiot, M. Etrillard, R. Bataille, B. Klein. A highly sensitive quantitative bioassay for human interleukin-11. *Journal of immunological methods*. **1994**. 173(1):19-26. doi:10.1016/0022-1759(94)90278-x.
177. Zhang, X. G., J. P. Gaillard, N. Robillard, Z. Y. Lu, Z. J. Gu, M. Jourdan, J. M. Boiron, R. Bataille, B. Klein. Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma. *Blood*. **1994**. 83(12):3654-3663. PMID:8204890.
178. Rimokh, R., F. Berger, C. Bastard, B. Klein, M. French, E. Archimbaud, J. P. Rouault, B. Santa Lucia, L. Duret, M. Vuillaume. Rearrangement of CCND1 (BCL1/PRAD1) 3' untranslated region in mantle-cell lymphomas and t(11q13)-associated leukemias. *Blood*. **1994**. 83(12):3689-3696. PMID:8204893.
179. Liautard, J., J. P. Gaillard, J. C. Mani, F. Montero-Julian, C. Duperray, Z. Y. Lu, M. Jourdan, B. Klein, H. Brailly, J. Brochier. Epitope analysis of human IL-6 receptor gp80 molecule with monoclonal antibodies. *European cytokine network*. **1994**. 5(3):293-300.

PMID:7524715.

180. Zhang, X. G., J. J. Gu, Z. Y. Lu, K. Yasukawa, G. D. Yancopoulos, K. Turner, M. Shoyab, T. Taga, T. Kishimoto, R. Bataille. Ciliary neurotropic factor, interleukin 11, leukemia inhibitory factor, and oncostatin M are growth factors for human myeloma cell lines using the interleukin 6 signal transducer gp130. *The Journal of Experimental Medicine*. **1994**. 179(4):1337-1342. doi:10.1084/jem.179.4.1337.
181. Rodriguez, C., C. Theillet, M. Portier, R. Bataille, B. Klein. Molecular analysis of the IL-6 receptor in human multiple myeloma, an IL-6-related disease. *FEBS letters*. **1994**. 341(2-3):156-161. doi:10.1016/0014-5793(94)80448-6.
182. Beck, J. T., S.-M. Hsu, J. Wijdenes, R. Bataille, B. Klein, D. Vesole, K. Hayden, S. Jagannath, B. Barlogie. Alleviation of Systemic Manifestations of Castleman's Disease by Monoclonal Anti-Interleukin-6 Antibody. *New England Journal of Medicine*. **1994**. 330(9):602-605. doi:10.1056/NEJM199403033300904.
183. Montero-Julian, F. A., J. Liautard, S. Flavetta, F. Romagné, J. P. Gaillard, J. Brochier, B. Klein, H. Brailly. Immunoassay for functional human soluble interleukin-6 receptor in plasma based on ligand/receptor interactions. *Journal of Immunological Methods*. **1994**. 169(1):111-121. doi:10.1016/0022-1759(94)90130-9.
184. Boccadoro, M., G. Gallone, R. Frieri, A. Pileri, R. Bataille, B. Klein. Plasma cell labeling index, beta 2-microglobulin, and C-reactive protein: what is the best combination for myeloma prognosis? *Blood*. **1993**. 82(11):3507-3508. PMID:8241520.
185. Portier, M., X. G. Zhang, E. Ursule, D. Lees, M. Jourdan, R. Bataille, B. Klein. Cytokine gene expression in human multiple myeloma. *British journal of haematology*. **1993**. 85(3):514-520. doi:10.1111/j.1365-2141.1993.tb03341.x.
186. Lu, Z. Y., H. Brailly, J. F. Rossi, J. Wijdenes, R. Bataille, B. Klein. Overall interleukin-6 production exceeds 7 mg/day in multiple myeloma complicated by sepsis. *Cytokine*. **1993**. 5(6):578-582. doi:10.1016/s1043-4666(05)80007-9.
187. Raynaud, S. D., S. Bekri, D. Leroux, J. Grosgeorge, B. Klein, C. Bastard, P. Gaudray, M. P. Simon. Expanded range of 11q13 breakpoints with differing patterns of cyclin D1 expression in B-cell malignancies. *Genes, Chromosomes & Cancer*. **1993**. 8(2):80-87. doi:10.1002/gcc.2870080204.
188. Portier, M., X. G. Zhang, E. Caron, Z. Y. Lu, R. Bataille, B. Klein. gamma-Interferon in multiple myeloma: inhibition of interleukin-6 (IL-6)-dependent myeloma cell growth and downregulation of IL-6-receptor expression in vitro. *Blood*. **1993**. 81(11):3076-3082. PMID:8499642.
189. Gaillard, J. P., R. Bataille, H. Brailly, C. Zuber, K. Yasukawa, M. Attal, N. Maruo, T. Taga, T. Kishimoto, B. Klein. Increased and highly stable levels of functional soluble interleukin-6 receptor in sera of patients with monoclonal gammopathy. *European journal of immunology*. **1993**. 23(4):820-824. doi:10.1002/eji.1830230408.

190. Commes, T., G. Clofent, N. Ghanem, X. G. Zhang, M. P. Lefranc, R. Bataille, B. Klein. Analysis of the B-cell compartment in plasma cell leukemia and multiple myeloma: immunoglobulin gene rearrangement of EBV-infected B-cell lines. *Leukemia*. **1993**. 7(4):609-617. PMID:7681918.
191. Bataille, R., X. G. Zhang, J. Wijdenes, J. F. Schved, B. Klein. Effects of an anti-interleukin-6 (IL-6) murine monoclonal antibody in a patient with acute monoblastic leukemia. *Medical oncology and tumor pharmacotherapy*. **1993**. 10(4):185-188. doi:10.1007/BF02989668.
192. Portier, M., J. P. Molès, G. R. Mazars, P. Jeanteur, R. Bataille, B. Klein, C. Theillet. p53 and RAS gene mutations in multiple myeloma. *Oncogene*. **1992**. 7(12):2539-2543. PMID:1461658.
193. Lu, Z. Y., J. Brochier, J. Wijdenes, H. Brailly, R. Bataille, B. Klein. High amounts of circulating interleukin (IL)-6 in the form of monomeric immune complexes during anti-IL-6 therapy. Towards a new methodology for measuring overall cytokine production in human in vivo. *European journal of immunology*. **1992**. 22(11):2819-2824. doi:10.1002/eji.1830221110.
194. Bataille, R., C. Duperray, X. G. Zhang, J. Brochier, B. Klein. CD5 B lymphocyte antigen in monoclonal gammopathy. *American journal of hematology*. **1992**. 41(2):102-106. doi:10.1002/ajh.2830410207.
195. Klein, B., Z. Y. Lu, R. Bataille. Clinical applications of IL6 inhibitors. *Research in immunology*. **1992**. 143(7):774-776. doi:10.1016/0923-2494(92)80022-d.
196. Bataille, R., M. Boccadoro, B. Klein, B. Durie, A. Pileri. C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system. *Blood*. **1992**. 80(3):733-737. PMID:1638024.
197. Bataille, Rég., B. Klein. C-reactive protein levels as a direct indicator of interleukin-6 levels in humans in vivo. *Arthritis & Rheumatism*. **1992**. 35(8):982-983. doi:10.1002/art.1780350824.
198. Portier, M., D. Lees, E. Caron, M. Jourdan, J. M. Boiron, R. Bataille, B. Klein. Up-regulation of interleukin (IL)-6 receptor gene expression in vitro and in vivo in IL-6 deprived myeloma cells. *FEBS letters*. **1992**. 302(1):35-38. doi:10.1016/0014-5793(92)80278-o.
199. Mazars, G. R., M. Portier, X. G. Zhang, M. Jourdan, R. Bataille, C. Theillet, B. Klein. Mutations of the p53 gene in human myeloma cell lines. *Oncogene*. **1992**. 7(5):1015-1018. PMID:1373872.
200. Bouanani, M., R. Bataille, B. Klein, B. Pau, M. Bastide. Conserved natural humoral immunity to thyroglobulin in patients with multiple myeloma. *British journal of haematology*. **1992**. 81(1):62-66. doi:10.1111/j.1365-2141.1992.tb08172.x.

201. Klein, B., R. Bataille. Cytokine network in human multiple myeloma. *Hematology/oncology clinics of North America*. **1992**. 6(2):273-284. PMID:1582974.
202. Bataille, R., D. Chappard, B. Klein. Mechanisms of bone lesions in multiple myeloma. *Hematology/oncology clinics of North America*. **1992**. 6(2):285-295. PMID:1582975.
203. Zhang, X. G., R. Bataille, J. Widjenes, B. Klein. Interleukin-6 dependence of advanced malignant plasma cell dyscrasias. *Cancer*. **1992**. 69(6):1373-1376. doi:10.1002/1097-0142(19920315)69:6%3C1373::aid-cncr2820690612%3E3.0.co;2-1.
204. Bataille, R., X. G. Zhang, C. Duperray, G. Rajzbaum, J. Brochier, B. Klein. Major immunoglobulin capping deficiency in the peripheral blood B cells of patients with Sjögren's syndrome. *Immunology*. **1992**. 75(3):550-552. PMID:1572701.
205. Bataille, R., B. Klein. Etiology of Paget's disease of bone: a new perspective. *Calcified Tissue International*. **1992**. 50(3):293-294. doi:10.1007/BF00296296.
206. Klein, B., Z. Y. Lu, J. P. Gaillard, J. L. Harousseau, R. Bataille. Inhibiting IL-6 in human multiple myeloma. *Current topics in microbiology and immunology*. **1992**. 182:237-244. doi:10.1007/978-3-642-77633-5_29.
207. Bataille, R., B. Klein. Role of interleukin-6 in multiple myeloma. *Annales de medecine interne*. **1992**. 143 Suppl 1:77-79. PMID:1300892.
208. Bataille, R., D. Chappard, B. Klein. The critical role of interleukin-6, interleukin-1B and macrophage colony-stimulating factor in the pathogenesis of bone lesions in multiple myeloma. *International journal of clinical & laboratory research*. **1992**. 21(4):283-287. doi:10.1007/BF02591662.
209. Jourdan, M., X. G. Zhang, M. Portier, J. M. Boiron, R. Bataille, B. Klein. IFN-alpha induces autocrine production of IL-6 in myeloma cell lines. *Journal of immunology (Baltimore, Md. : 1950)*. **1991**. 147(12):4402-4407. PMID:1753108.
210. Roux, P., B. Verrier, B. Klein, M. Niccolino, L. Marty, C. Alexandre, M. Piechaczyk. Retrovirus-mediated gene transfer of a human c-fos cDNA into mouse bone marrow stromal cells. *Oncogene*. **1991**. 6(11):2155-2160. PMID:1658710.
211. Klein, B., J. Wijdenes, X. G. Zhang, M. Jourdan, J. M. Boiron, J. Brochier, J. Liautard, M. Merlin, C. Clement, B. Morel-Fournier. Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. *Blood*. **1991**. 78(5):1198-1204. PMID:1715218.
212. Pujol, J. L., B. Klein, P. Godard, L. Dussourd d'Hinterland, F. B. Michel. Bacterial ribosomal immunostimulants prime alveolar macrophages in vivo to produce interleukin 1 in vitro. *Chest*. **1991**. 100(3):644-648. doi:10.1378/chest.100.3.644.
213. Duperray, C., R. Bataille, J. M. Boiron, I. A. Haagen, J. F. Cantaloube, X. G. Zhang, C. Boucheix, B. Klein. No expansion of the pre-B and B-cell compartments in the bone

- marrow of patients with multiple myeloma. *Cancer research*. **1991**. 51(12):3224-3228. PMID:1904006.
214. Zhang, X. G., R. Bataille, M. Jourdan, S. Saeland, J. Banchereau, P. Mannoni, B. Klein. Granulocyte-macrophage colony-stimulating factor synergizes with interleukin-6 in supporting the proliferation of human myeloma cells. *Blood*. **1990**. 76(12):2599-2605. PMID:2265252.
215. Duperray, C., J. M. Boiron, C. Boucheix, J. F. Cantaloube, T. Lavabre-Bertrand, M. Attal, J. Brochier, D. Maraninchi, R. Bataille, B. Klein. The CD24 antigen discriminates between pre-B and B cells in human bone marrow. *Journal of immunology (Baltimore, Md. : 1950)*. **1990**. 145(11):3678-3683. PMID:1700990.
216. Klein, B., X. G. Zhang, M. Jourdan, J. M. Boiron, M. Portier, Z. Y. Lu, J. Wijdenes, J. Brochier, R. Bataille. Interleukin-6 is the central tumor growth factor in vitro and in vivo in multiple myeloma. *European cytokine network*. **1990**. 1(4):193-201. PMID:2104241.
217. Klein, B., R. Bataille. [Advances in the biology of multiple myeloma]. *Pathologie-biologie*. **1990**. 38(8):820-821. PMID:2274372.
218. Parant, M. R., B. Klein, H. Vial. Abnormal behavior of protein kinase C in the human myeloma cell line, RPMI 8226. *FEBS letters*. **1990**. 269(2):331-335. doi:10.1016/0014-5793(90)81187-s.
219. Commes, T., G. Clofent, M. Jourdan, R. Bataille, B. Klein. Human natural killer cells suppress the proliferation of B cells. *Immunology letters*. **1990**. 24(1):57-61. doi:10.1016/0165-2478(90)90036-p.
220. Klein, B., X. G. Zhang, M. Jourdan, M. Portier, R. Bataille. Interleukin-6 is a major myeloma cell growth factor in vitro and in vivo especially in patients with terminal disease. *Current topics in microbiology and immunology*. **1990**. 166:23-31. doi:10.1007/978-3-642-75889-8_3.
221. Clofent, G., F. Brockly, T. Commes, M. P. Lefranc, R. Bataille, B. Klein. No preferential use of the VH(V) family in human multiple myeloma. *British journal of haematology*. **1989**. 73(4):486-490. doi:10.1111/j.1365-2141.1989.tb00285.x.
222. Bataille, R., M. Jourdan, X. G. Zhang, B. Klein. Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. *The Journal of clinical investigation*. **1989**. 84(6):2008-2011. doi:10.1172/JCI114392.
223. Zhang, X. G., B. Klein, R. Bataille. Interleukin-6 is a potent myeloma-cell growth factor in patients with aggressive multiple myeloma. *Blood*. **1989**. 74(1):11-13. PMID:2787674.
224. Bataille, R., B. Klein, B. G. Durie, J. Sany. Interrelationship between autoimmunity and B-lymphoid cell oncogenesis in humans. *Clinical and experimental rheumatology*. **1989**. 7(3):319-328. PMID:2667833.

225. Clofent, G., B. Klein, T. Commes, C. Vincent, N. Ghanem, G. Lenoir, M. P. Lefranc, R. Bataille. Limiting dilution cloning of B cells from patients with multiple myeloma: emergence of non-malignant B-cell lines. *International journal of cancer*. **1989**. 43(4):578-586. doi:10.1002/ijc.2910430408.
226. Bataille, R., B. Klein, M. Jourdan, J. F. Rossi, B. G. Durie. Spontaneous secretion of tumor necrosis factor-beta by human myeloma cell lines. *Cancer*. **1989**. 63(5):877-880. doi:10.1002/1097-0142(19890301)63:5%3C877::aid-cncr2820630514%3E3.0.co;2-6.
227. Clofent, G., B. Klein, T. Commes, N. Ghanem, M. P. Lefranc, R. Bataille. No detectable malignant B cells in the peripheral blood of patients with multiple myeloma. *British journal of haematology*. **1989**. 71(3):357-361. doi:10.1111/j.1365-2141.1989.tb04292.x.
228. Klein, B., X. G. Zhang, M. Jourdan, J. Content, F. Houssiau, L. Aarden, M. Piechaczyk, R. Bataille. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. *Blood*. **1989**. 73(2):517-526. PMID:2783861.
229. Duperray, C., B. Klein, B. G. Durie, X. Zhang, M. Jourdan, P. Poncelet, F. Favier, C. Vincent, J. Brochier, G. Lenoir. Phenotypic analysis of human myeloma cell lines. *Blood*. **1989**. 73(2):566-572. PMID:2537114.
230. Commes, T., B. Klein, M. Jourdan, G. Clofent, F. Houssiau, J. Grenier, R. Bataille. The defect in peripheral blood B-cell activation in patients with multiple myeloma is not due to a deficiency in the production of B-cell growth and differentiation factors. *Journal of clinical immunology*. **1989**. 9(1):65-73. doi:10.1007/BF00917129.
231. Bataille, R., B. G. Durie, B. Klein. Antibody specificity of the human monoclonal immunoglobulins: the elusive target antigen. *Autoimmunity*. **1989**. 4(3):181-189. doi:10.3109/08916938909003048.
232. Rossi, J. F., T. Commes, J. Grenier, M. Jourdan, B. Chichehian, B. Klein. Production of B-cell growth factor interleukin 2 and gamma interferon by peripheral blood lymphocytes from patients with chronic lymphocytic leukemia of B-cell type. *American journal of hematology*. **1988**. 29(4):183-188. doi:10.1002/ajh.2830290402.
233. Bataille, R., B. Klein. CD5 positive B lymphocytes: a link between autoimmunity and B-cell oncogenesis. *Anticancer research*. **1988**. 8(4):707-710. PMID:2460021.
234. Zhang, X. G., B. Klein, C. Duperray, J. Brochier, R. Bataille. Delay and not deficiency in cap formation of peripheral blood B cells in patients with multiple myeloma. *Journal of clinical immunology*. **1988**. 8(4):244-249. doi:10.1007/BF00916552.
235. Rossi, J. F., B. Klein, T. Commes, M. Jourdan, C. Janbon. Interleukin 2 production in bone marrow of normal individuals and patients associated with B-cell chronic lymphocytic leukaemia. *British journal of haematology*. **1988**. 68(2):207-212. doi:10.1111/j.1365-2141.1988.tb06191.x.
236. Danel, L., C. Vincent, F. Rousset, B. Klein, R. Bataille, M. Flacher, B. G. Durie, J. P.

- Revillard. Estrogen and progesterone receptors in some human myeloma cell lines and murine hybridomas. *Journal of Steroid Biochemistry*. **1988**. 30(1-6):363-367. doi:10.1016/0022-4731(88)90124-0.
237. Klein, B., M. Jourdan, A. Vazquez, B. Dugas, R. Bataille. Production of growth factors by human myeloma cells. *Cancer research*. **1987**. 47(18):4856-4860. PMID:3113725.
238. Combe, B., M. Andary, B. Klein, J. Clot, J. Sany. Regulation of interleukin-2 production in rheumatoid arthritis. *The Journal of Rheumatology*. **1987**. 14(2):226-229. PMID:3496450.
239. Bataille, R., B. Klein. Autoimmune conditions induced by epithelial solid tumors. *Rheumatology international*. **1987**. 7(6):231-233. doi:10.1007/BF00270521.
240. Commes, T., B. Klein, M. Jourdan, R. Bataille. Production of interleukin 2 in multiple myeloma. *Clinical and experimental immunology*. **1986**. 63(3):533-540. PMID:3486731.
241. Dugas, B., A. Vazquez, B. Klein, J. Delfraissy, M. Rammou, J. Gerard, P. Galanaud. Early events in human B cell activation: metabolic pathways vary according to the first signal used. *European Journal of Immunology*. **1986**. 16(12):1609-1614. doi:10.1002/eji.1830161222.
242. Rossi, J. F., B. Klein, T. Commes, M. Jourdan. Interleukin 2 production in B cell chronic lymphocytic leukemia. *Blood*. **1985**. 66(4):840-847. PMID:3876123.
243. Jourdan, M., T. Commes, B. Klein. Control of human T-colony formation by interleukin-2. *Immunology*. **1985**. 54(2):249-253. PMID:3871418.
244. Rey, A., B. Klein, C. Ilnicki, M. Jourdan, B. Serrou. The role of interleukin-2 in T colony formation by human pre-T cells (pTCFC). *Clinical and experimental immunology*. **1984**. 58(1):154-160. PMID:6332691.
245. Rey, A., B. Klein, M. Rucheton, J. Caraux, D. Zagury, C. Thierry, B. Serrou. Human autologous rosettes. *Cellular Immunology*. **1984**. 86(1):155-164. doi:10.1016/0008-8749(84)90368-X.
246. Noma, T., B. Klein, J. Yata, B. Serrou. Low dose of deoxyguanosine increases IL-2 receptors of IL-2-dependent cultured T cells. *Immunology*. **1984**. 52(2):247-252. PMID:6610631.
247. Noma, T., B. Klein, D. Cupissol, J. Yata, B. Serrou. Increased sensitivity of IL2-dependent cultured T cells and enhancement of in vitro IL2 production by human lymphocytes treated with Bestatin. *International journal of immunopharmacology*. **1984**. 6(2):87-92. doi:10.1016/0192-0561(84)90001-8.
248. Klein, B., J. J. Akouala, C. Le Bousse-Kerdiles, F. Smadja-Joffe, C. Jasmin. Hematopoietic precursors in disease induced by the myeloproliferative sarcoma virus. *Blood*. **1983**. 62(2):305-307. PMID:6307431.

249. Klein, B., J. J. Akouala, C. Le Bousse-Kerdiles, F. Smadja-Joffe, C. Jasmin. Hematopoietic precursors in disease induced by the myeloproliferative sarcoma virus. *Blood*. **1983**. 62(2):305-307. PMID:6307431.
250. Fagg, B., W. Ostertag, B. Klein, C. Le Bousse. Myeloproliferative sarcoma virus: its effects on erythropoiesis in adult DBA/2J mice. *Journal of cellular physiology*. **1983**. 116(1):16-20. doi:10.1002/jcp.1041160104.
251. Klein, B., A. Rey, M. Jourdan, B. Serrou. The role of interleukin 1 and interleukin 2 in human T colony formation. *Cellular immunology*. **1983**. 77(2):348-356. doi:10.1016/0008-8749(83)90035-7.
252. Klein, B., A. Rey, M. Jourdan, M. H. Donnadieu, B. Serrou. Induction of human T colony formation by phorbol myristate acetate. *Scandinavian journal of immunology*. **1983**. 17(4):329-334. doi:10.1111/j.1365-3083.1983.tb00797.x.
253. Rey, A., B. Klein, D. Zagury, C. Thierry, B. Serrou. Diminished interleukin-2 activity production in cancer patients bearing solid tumors and its relationship with natural killer cells. *Immunology Letters*. **1983**. 6(3):175-178. doi:10.1016/0165-2478(83)90101-3.
254. Le Bousse-Kerdiles, M. C., F. Smadja-Joffe, B. Klein, C. Jasmin, M. Comisso, W. Ostertag. Myeloproliferative syndrome induced by MPSV in DBA/2 mice: presence of a mixed-colonies promoting activity (MPA) in the spleen. *Blood*. **1983**. 61(3):520-524. PMID:6297639.
255. Klein, B., A. Rey, M. Jourdan, M. H. Donnadieu, B. Serrou. Modulation of PHA-induced T colony formation by phorbol myristic acetate. *Clinical and experimental immunology*. **1983**. 51(2):375-380. PMID:6601556.
256. Klein, B., J. Chaintreuil, A. Crastes de Paulet, B. Serrou. Suppressor effect of prostaglandins on T colony formation. *Immunology*. **1983**. 48(2):337-342. PMID:6600443.
257. Mori, K. J., F. Smadja-Joffe, F. Barre-Sinoussi, M. C. Le Bousse-Kerdiles, B. Klein, B. Caillou, W. Ostertag, C. Jasmin, V. Degiorgis. Myeloproliferative Sarcoma Virus stimulates pluripotent hematopoietic stem cells and provokes tumoral transformation of the hematopoietic microenvironment in vitro. *Leukemia research*. **1983**. 7(1):77-86. doi:10.1016/0145-2126(83)90060-7.
258. Klein, B., C. Le Bousse-Kerdiles, F. Smadja-Joffe, I. Pragnell, W. Ostertag, C. Jasmin. A study of added GM-CSF independent granulocyte and macrophage precursors in mouse spleen infected with myeloproliferative sarcoma virus (MPSV). *Experimental hematology*. **1982**. 10(4):373-382. PMID:6284533.
259. Smadja-Joffe, F., M. C. Le Bousse-Kerdiles, B. Klein, E. P. Malaise, C. Jasmin, V. Degiorgis. Cellular proliferation kinetics of the murine sarcoma induced by the Moloney sarcoma virus. *Cell and tissue kinetics*. **1982**. 15(2):169-178. doi:10.1111/j.1365-2184.1982.tb01035.x.

260. Klein, B., J. Caraux, P. Thomas, P. Goube De Laforest. Nature and mechanisms of action of co-operating cells controlling human T-colony formation. *Immunology*. **1982**. 45(2):265-271. PMID:6977480.
261. Caraux, J., B. Klein, C. Thierry, B. Serrou. Amplification of the polyclonal activation of human T cells. I. Null-cell products promote the polyclonal proliferation of T cells. *Immunology*. **1982**. 45(2):257-263. PMID:6977479.
262. Pragnell, I. B., A. Fusco, C. Arbuthnott, F. Smadja-Joffe, B. Klein, C. Jasmin, W. Ostertag. Analysis of the myeloproliferative sarcoma virus genome: limited changes in the prototype lead to altered target cell specificity. *Journal of virology*. **1981**. 38(3):952-957. doi:10.1128/JVI.38.3.952-957.1981.
263. Klein, B., C. Le Bousse, B. Fagg, F. Smajda-Joffe, K. Vehmeyer, K. J. Mori, C. Jasmin, W. Ostertag. Effects of myeloproliferative sarcoma virus on the pluripotential stem cell and granulocyte precursor cell populations of DBA/2 mice. *Journal of the National Cancer Institute*. **1981**. 66(5):935-940. PMID:6262560.
264. Klein, B., J. Caraux, C. Thierry, L. Gauci, A. Causse, B. Serrou. Human T-lymphocyte colonies: generation of colonies in different lymphocyte subpopulations. *Immunology*. **1981**. 43(1):39-45. PMID:6972905.
265. Smadja-Joffe, F., M. C. Le Bousse-Kerdiles, D. Costagliola, B. Klein, E. P. Malaise, C. Jasmin. Cellular proliferation in the spleen of DBA/2 mice infected with a myeloproliferative sarcoma virus(MPSV). *Experimental hematology*. **1981**. 9(2):137-148. PMID:6263661.
266. Klein, B., J. Caraux, A. Causse, C. Thierry, B. Serrou. Human T lymphocyte colonies. I. Surface markers and cytotoxic potential of colony cells. *Biomedicine / [publiee pour l'A.A.I.C.I.G.]*. **1981**. 34(1):34-39. PMID:6971656.
267. Le Bousse-Kerdiles, M. C., C. Jasmin, F. Smadja-Joffe, B. Klein, I. Pragnell, W. Ostertag. Myeloproliferative sarcoma virus (MPSV), a new tool for the study of hematopoiesis. *Blood cells*. **1981**. 7(1):105-123. PMID:6318868.
268. Allouche, M., H. G. Delbrück, B. Klein, R. Masse, A. Matar, M. Morin, J. Lafuma, C. Jasmin. Malignant bone tumours induced by a local injection of colloidal radioactive ¹⁴⁴Cerium in rats as a model for human osteosarcomas. *International journal of cancer*. **1980**. 26(6):777-782. doi:10.1002/ijc.2910260611.
269. Klein, B., P. D. M. MacDonald. The multitype continuous-time Markov branching process in a periodic environment. *Advances in Applied Probability*. **1980**. 12(1):81-93. doi:10.2307/1426495.
270. Ostertag, W., K. Vehmeyer, B. Fagg, I. B. Pragnell, W. Paetz, M. C. Le Bousse, F. Smadja-Joffe, B. Klein, C. Jasmin, H. Eisen. Myeloproliferative virus, a cloned murine sarcoma virus with spleen focus-forming properties in adult mice. *Journal of virology*. **1980**. 33(2):573-582. doi:10.1128/JVI.33.2.573-582.1980.

271. Le Bousse-Kerdiles, M. C., F. Smadja-Joffe, B. Klein, B. Caillou, C. Jasmin. Study of a virus-induced myeloproliferative syndrome associated with tumor formation in mice. *European journal of cancer*. **1980**. 16(1):43-51. doi:10.1016/0014-2964(80)90106-1.
272. Wangenheim, H. R. von, R. Schofield, S. Kyffin, B. Klein. Studies on erythroid-committed precursor cells in the polycythaemic mouse. *Biomedicine / [publiee pour l'A.A.I.C.I.G.]*. **1977**. 27(9-10):337-340. PMID:606309.
273. Klein, B., S. Pals, R. Masse, J. Lafuma, M. Morin, N. Binart, J. R. Jasmin, C. Jasmin. Studies of bone and soft-tissue tumours induced in rats with radioactive cerium chloride. *International Journal of Cancer*. **1977**. 20(1):112-119. doi:10.1002/ijc.2910200118.
274. Jasmin, J. R., C. Brocheriou, B. Klein, M. Morin, F. Smadja-Joffe, P. Cernea, C. Jasmin. Induction in Rats of Paranasal Sinus Carcinomas With Radioactive Cerium Chloride. *JNCI: Journal of the National Cancer Institute*. **1977**. 58(2):423-427. doi:10.1093/jnci/58.2.423.
275. Klein, B., A. J. Valleron. A compartmental model for the study of diurnal rhythms in cell proliferation. *Journal of theoretical biology*. **1977**. 64(1):27-42. doi:10.1016/0022-5193(77)90112-6.
276. Smadja-Joffe, F., B. Klein, C. Kerdiles, L. Feinendegen, C. Jasmin. STUDY OF CELL DEATH IN FRIEND LEUKAEMIA. *Cell Proliferation*. **1976**. 9(2):131-145. doi:10.1111/j.1365-2184.1976.tb01261.x.
277. Jasmin, C., F. S. Joffe, B. Klein, C. Kerdiles-LeBousse. Physiopathology of human and virus-induced murine leukemias. *Cancer research*. **1976**. 36(2 pt 2):603-607. PMID:175921.
278. Smadja-Joffe, F., C. Jasmin, C. Kerdiles, B. Klein. Friend leukemia: a model for the physiopathology of human chronic leukemia. *European journal of cancer*. **1975**. 11(12):831-840. doi:10.1016/0014-2964(75)90081-x.
279. Smadja-Joffe, F., B. Klein, C. Kerdiles, C. Jasmin. Kinetic model of Friend virus-induced leukemia. *Bibliotheca haematologica*. **1975**. (43):451-452. doi:10.1159/000399190.
280. Klein, B., A. J. Valleron. Mathematical modelling of cell cycle and chronobiology: preliminary results. *Biomedicine / [publiee pour l'A.A.I.C.I.G.]*. **1975**. 23(6):214-217. PMID:1240010.
- 281.